Slide 1: FDC Limited Investor Presentation Q3FY23
FDC LIMITED Investor Presentation Q3FY23 www.fdcindia.com 1
Slide 2: Disclaimer
DISCLAIMER This report may contain certain statements that might be considered forward looking. These statements are subject to certain risk and uncertainties, since they are based on certain assumptions and expectations of future events. Actual results may differ materially from those expressed in
Slide 3: Platform to deliver sustainable value
Platform to deliver sustainable value 1 2 3 Best-in-class manufacturing Strong Domestic Business facilities & regulatory Strong Financials Multiple levers, high growth track record brands to anchor growth Portfolio of high quality High Return on Capital Zifi – Category Creator in manufacturi
Slide 4: Multiple Levers to drive growth
Multiple Levers to drive growth 1(a) (Source: IQVIA-Moving Annual Total Turnover- MAT Dec 2022) Q3FY23 Anti-Infectives 1%4% 3% Gastro Intestinal 3% VMN Revenue Domestic, 78% 5% 4% 35% Derma Mix Ophthal 7% Cardiac Gynaec. Export, 22% 9% Respiratory Antiviral 29% Others Domestic Sales Export Sales 19%
Slide 5: Multiple Top Brands to anchor growth
Multiple Top Brands to anchor growth 1(a) Brand Molecule Rank Rs. crs MS % Electral Oral Electrolytes ❶ 360 74.6% Zifi Cefixime ❶ 337 25.2% Enerzal Energy Drinks ❶ 159 37.5% Vitcofol Folic acid + Cyanocobalamin + Nicotinamide ❽ 87 2.6% Zifi CV Cefixime + Clav. ❶ 81 48.3% Zathrin Azithromycin ❺ 62 4.
Slide 6: Electral – Category Creator & Consistent Leader in Oral Rehydration Salts
1(b) Electral – Category Creator & Consistent Leader in Oral Rehydration Salts Electral –Brand synomous with product category In an otherwise fragmented market (Market Share) (Market Shares of Other Players) Market Share in MAT Dec 20 Market Share in MAT Dec 22 13.8% 12.9% 73.7% 71.8% 74.6% 3.5% 3.6
Slide 7: Zifi – Category Leader in CEFIXIME
1(c) Zifi – Category Leader in CEFIXIME Zifi – Consistent Category Leader In an otherwise fragmented market (Market Share) (Market Shares of Other Players) Market Share in MAT Dec 20 Market Share in MAT Dec 22 22.7% 23.1% 24.2% 24.6% 25.2% MAT 2020/12 MAT 2021/12 MAT 2022/12 5.4% 5.9% 5.2% 5.7% 6.5%
Slide 8: Enerzal – Category Leader in Energy Drinks
1(d) Enerzal– Category Leader in Energy Drinks Enerzal – Consistent Category Leader In an otherwise fragmented market (Market Share) (Market Shares of Other Players) Market Share in MAT Dec 20 Market Share in MAT Dec 22 22.1% 19.1% 36.8% 33.3% 37.5% 14.6% 13.7% MAT 2020/12 MAT 2021/12 MAT 2022/12 12
Slide 9: Among top Corporates in IPM in Prescriptions by Core Specialties
Among top 20 Corporates in IPM in Prescriptions by Core Specialties in Apr-Dec YTD 1e) % Growth Specialities FDC IPM % MS Rank Overall 38 34 5.6 13 GP-NON.MBBS 39 35 9.6 5 GP - MBBS 47 28 7.1 9 PEDIATRICIAN 50 44 5.7 18 ENT SPECIALIST 29 29 5.3 15 OPHTHALMOLOGIST 2 22 5.6 9 (Source: IQVIA-Medical Au
Slide 10: Manufacturing Facilities
2 (a) Manufacturing Facilities Sinnar Sinnar Dosage Form Baddi Goa 1/2 Goa 3 Waluj (Food) (Form) Tablet/Capsule Baddi Dry Syrup Liquid Oral Powder Ophthalmic Ear Drops Sinnar - Food Plant Foods Waluj Sinnar – Form Plant Roha Goa (3 Facilities) API Plant Food Plant Formulation Plant Source: Internal
Slide 11: Top Countries: Export Sale of APIs & Formulations Q3FY23
2 (b) TOP 10 Countries: Export Sale of APIs & Formulations Q3FY23 Export Formulation Sales - 65Crs Export API Sales - 20crs 14% 16% USA Japan 23% 2% Malaysia Germany 3% UK USA 2% New Zealand South Korea 3% 3% Tanzania Algeria 3% 4% Iran Chile 4% 52% Australia Nepal 4% 14% UAE 4% Myanmar 5% Taiwan 4%
Slide 12: Quarterly Performance
Quarterly Performance 3(a) 45% 19% 11% 13% 6% 8% -6% 3% 312 445 396 341 337 493 447 407 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Sales (in Crs) YOY Sales Growth % 31% 26% 19% 20% 18% 17% 16% 9% 2.49 5.93 4.36 1.87 0.85 4.37 3.07 2.44 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3
Slide 13: Quarterly Performance
Quarterly Performance 3(a) in crs. (except EPS) Q3FY23 Q3FY22 YoY % Revenue from operations Revenue from operations 407 341 19% Other income 19 13 43% Q3FY22 341 Total Income 425 354 20% 19% Operating Expenses 360 298 21% Q3FY23 407 EBITDA 65 57 15% Finance Cost 1.2 0.8 40% Depreciation 10 9 9% EPS
Slide 14: For updates and company information, please visit our website
For updates and company information, please visit our website i.e. www.fdcindia.com For specific queries, kindly email on investors@fdcindia.com
Slide 15: Thank You
THANK YOU 8